Jade Biosciences, Inc. quarterly report, Q1 FY2024

Filing identity and reporting period

Important: The supplied filing is Aerovate Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2024, not a Jade Biosciences, Inc. filing. The summary below reflects Aerovate’s filing.

Business context

Aerovate is a clinical-stage biopharmaceutical company developing AV-101, an inhaled dry-powder formulation of imatinib for pulmonary arterial hypertension (PAH). It has no approved products and has not generated product revenue. The company’s business depends on the development and potential commercialization of AV-101.

Financial results and liquidity

At March 31, 2024, cash and cash equivalents were $9.1 million and short-term investments were $90.2 million, totaling $99.3 million in cash and investments. Current assets were $103.2 million and current liabilities were $15.5 million. Total liabilities were $15.9 million; the company reported no long-term debt. No revenue or gross margin was reported, so operating margins are not meaningful.

Management said existing cash, cash equivalents and short-term investments were expected to fund planned operations into 2026, based on current plans. Separately, it stated these resources should cover obligations for at least 12 months from the filing date. In April 2024, the company raised $23.6 million net through its at-the-market (ATM) program; approximately $6.0 million remained available under the program as of the filing date.

Material changes versus the prior comparable period

• Operating expenses rose $7.0 million year over year, driven primarily by a $6.6 million increase in R&D. The company attributed the R&D increase mainly to clinical-trial manufacturing costs, headcount and preclinical and regulatory costs.
• Net loss increased by $6.7 million, while operating cash use more than doubled, from $11.4 million to $23.7 million.
• Interest income increased to $1.4 million from $1.1 million, partly offsetting operating losses.
• From December 31, 2023, to March 31, 2024, cash and investments fell from $122.4 million to $99.3 million. The decline reflects operating cash use and investment activity; it excludes the subsequent April ATM proceeds.

Outlook, developments and principal risks

• In November 2023, Aerovate reported completion of enrollment of 202 patients in the Phase 2b portion of its global IMPAHCT trial and enrollment of the first patient in the Phase 3 portion. More than 120 Phase 3 sites were open and enrolling.
• The company expected to report Phase 2b topline data in June 2024, while noting timing depended on the final patient visit and database cleaning and lock. Phase 3 timing and size remained uncertain pending Phase 2b results.
• The Phase 2b study evaluates dose and pulmonary vascular resistance; the Phase 3 primary endpoint is six-minute walk distance. The filing cautions that prior oral-imatinib results and AV-101 Phase 1 results may not predict AV-101’s efficacy or tolerability in PAH patients.
• Management expects substantial R&D spending and losses to continue and anticipates needing additional capital. Financing may dilute shareholders or be unavailable on acceptable terms, potentially requiring development delays or reductions.
• Key risks include clinical efficacy and safety, trial enrollment and site delays, regulatory review of a drug-device combination and the proposed 505(b)(2) pathway, reliance on third-party clinical and manufacturing providers, and competition in PAH.
• Management reported no material legal proceedings and concluded disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2024.

Important facts for investors to verify

• Confirm issuer identity: this filing is for Aerovate Therapeutics, not Jade Biosciences.
• Review subsequent disclosures for the Phase 2b topline results expected in June 2024 and any resulting changes to the Phase 3 trial plan, size or timing.
• Assess the stated runway through 2026 against actual trial spending, operating cash use and any revised development plans.
• Verify the April 2024 ATM issuance, remaining ATM capacity, and share-count dilution; the filing reported 28,808,334 common shares outstanding as of May 9, 2024.
• Monitor AV-101 safety and efficacy data, enrollment progress, supplier and trial-site execution, and regulatory feedback.